Hybrid Capture-Based Tumor Sequencing and Copy Number Analysis to Confirm Origin of Metachronous Metastases in BRCA1-Mutant Cholangiocarcinoma Harboring a Novel YWHAZ-BRAF Fusion.
Huat C LimMeagan MontesionThomas BottonEric A CollissonSarah E UmetsuSpencer C BehrJohn D GordanPhil J StephensRobin Kate KelleyPublished in: The oncologist (2018)
Hybrid capture-based next-generation DNA sequencing assays can provide diagnostic clarity in patients with unusual patterns of metastasis and recurrence in which the pathologic diagnosis is ambiguous.To our knowledge, this is the first reported case of a YWHAZ-BRAF fusion in pancreaticobiliary cancer, and a very rare case of cholangiocarcinoma in the setting of a germline BRCA1 mutation.The patient's BRCA1 mutation and YWHAZ-BRAF fusion constitute potential targets for future therapy.
Keyphrases
- copy number
- rare case
- wild type
- mitochondrial dna
- metastatic colorectal cancer
- breast cancer risk
- genome wide
- single cell
- dna methylation
- neoadjuvant chemotherapy
- case report
- high throughput
- single molecule
- circulating tumor
- squamous cell carcinoma
- current status
- squamous cell
- stem cells
- mesenchymal stem cells
- risk assessment
- bone marrow
- human health
- radiation therapy
- cell therapy
- oxidative stress
- young adults
- nucleic acid
- rectal cancer